Show simple item record

dc.contributor.authorGarrido, María Antonia
dc.contributor.authorRuiz-Cabello Osuna, Francisco 
dc.contributor.authorGarrido Torres-Puchol, Federico 
dc.contributor.authorAptsiauri, Natalia
dc.date.accessioned2021-10-14T06:58:01Z
dc.date.available2021-10-14T06:58:01Z
dc.date.issued2021
dc.identifier.citationGarrido, M.A.; Perea, F.; Vilchez, J.R.; Rodríguez, T.; Anderson, P.; Garrido, F.; Ruiz-Cabello, F.; Aptsiauri, N. Copy Neutral LOH Affecting the Entire Chromosome 6 Is a Frequent Mechanism of HLA Class I Alterations in Cancer. Cancers 2021, 13, 5046. https://doi.org/10.3390/ cancers13205046es_ES
dc.identifier.urihttp://hdl.handle.net/10481/70833
dc.description.abstractTotal or partial loss of HLA class I antigens reduce the recognition of specific tumor peptides by cytotoxic T lymphocytes favoring cancer immune escape during natural tumor evolution. These alterations can be caused by genomic defects, such as loss of heterozygosity at chromosomes 6 and 15 (LOH-6 and LOH-15), where HLA class I genes are located. There is growing evidence indicating that LOH in HLA contributes to the immune selection of HLA loss variants and influences the resistance to immunotherapy. Nevertheless, the incidence and the mechanism of this chromosomal aberration involving HLA genes has not been systematically assessed in different types of tumors and often remains underestimated. Here, we used SNP arrays to investigate the incidence and patterns of LOH-6 and LOH-15 in a number of human cancer cell lines and tissues of different histological types. We observed that LOH in HLA is a common event in cancer samples with a prevalence of a copy neutral type of LOH (CN-LOH) that affects entire chromosome 6 or 15 and involves chromosomal duplications. LOH-6 was observed more often and was associated with homozygous HLA genotype and partial HLA loss of expression. We also discuss the immunologic and clinical implications of LOH in HLA on tumor clonal expansion and association with the cancer recurrence after treatment.es_ES
dc.description.sponsorshipISCIII Research Institute co-financed by the European Union and Ministerio de Ciencia e Innovación (FEDER-Fondo Europeo de Desarrollo Regional and National Plan 2020, MICIN) (PI17/00197, PI18/00826, and PID2020-115087GB-100)es_ES
dc.description.sponsorshipJunta de Andalucía in Spain (Group CTS-143 and B-CTS-410-UGR-20)es_ES
dc.description.sponsorshipConsejería de Salud, Junta de Andalucía through the contract “Nicolás Monardes” [C-0013-2018]es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsAtribución 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectCancer immune escapees_ES
dc.subjectHLA class Ies_ES
dc.subjectCopy-neutral loss of heterozygosity (CN-LOH)es_ES
dc.subjectAntigen presentationes_ES
dc.subjectBeta2-microglobulines_ES
dc.subjectCytotoxic T-cellses_ES
dc.subjectCancer immunotherapyes_ES
dc.titleCopy Neutral LOH Affecting the Entire Chromosome 6 Is a Frequent Mechanism of HLA Class I Alterations in Canceres_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.doi10.3390/cancers13205046


Files in this item

[PDF]

This item appears in the following Collection(s)

Show simple item record

Atribución 3.0 España
Except where otherwise noted, this item's license is described as Atribución 3.0 España